Visit the home page
Liberpro Advantage Market Milestones
Technology Advantage Market

 

Plasmid DNA as Biotherapeutics


Safer alternative than viruses for gene therapy

Ease of administering by direct injection

Advantages over conventional vaccines:

  • Low immunogenicity, thus allowing a course of multiple treatments
  • Improved stability of the vaccine
  • Stimulation of both B & T cell responses
  • Absence of any infectious agents
  • pDNA vector cassette is highly suitable for rapid development of various vaccine targets, e.g. personalized vaccines
  • Relative ease of large scale manufacture

Quality Control of Plasmid DNA


Quality Control of Plasmid DNA Table

* In compliance with FDAs Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications

Our advantage


Proven track record in plasmid manufacturing for 10 years

Proprietary technologies (patent-pending) & know-hows that reduce cost and shorten the whole production cycle

High pDNA yields (> 100 g per batch)

Our know-hows overcome the bottlenecks of common lab-scale techniques and meet all regulatory requirements

Stringent QA & QC measures guarantee quality of our plasmid DNA

Support from HKSAR government in process development

Continual improvement in manufacturing process through collaboration with the Hong Kong Institute of Biotechnology

Back to top